S
everai effective therapeutic options for hepatocellular carcinoma (HCCI have become available in recent years. Among them are regional chemoembolization, I percutaneous alcohol injection.:! cryosurgical J or microwave ablation, I subtotal hepatectomy (hepatic resection). :;·11 and totai hepatectomy with liver replacement (orthotopic liver transplantation I. 12·16 The outcome after hepatic resection (Hx) for HCC and that of orthotopic liver transplantation (OLTx) have been debated in several reports but without definite conclusions regarding the difference in long term survival. '7 . 20 In addition. each report contained only a limited number of early stage HCC tumors in patients with cirrhotic livers treated by Hx because of the smail numbers of such cases in the Western countries. Therefore. {he database of the National Cancer Center Hospital (Tokyo. Japanl and that of the University of Pitts-burgh Medical Center (Pittsburgh. PAl were exchanged to compare the long term overall and tumor free survival rates between Hx and OLTx in a large number of cirrhotic patients with HCC.
MATERIALS AND METHODS

Hepatic Resection Group
Between 1985 and 1994. 723 patients underwent primary Hx for the treatment of HCC at the National Cancer Center Hospital (NCCH). Tokyo. Japan. Portions of this experience were reported previously. 10.21 Among these 723 patients. 403 (55.7%) had histologically proven concomitant cirrhosis. Resection of the tumor(s) was incomplete in 109 patients (27. 0%) (58 patients had microscopic exposed tumors. 5 patients had positive surgical margins at the tumor thrombus in the portal vein. 45 patients underwent debulking resection due to limited liver function. and 1 patient had extrahepatic disease that was not removed). The remaining 294 cirrhotic patients (72.9%) who underwent complete resection of the tumors were selected for this study. The range of the follow-up period was 0.23-140 months (median. 46.0 months). The preoperative level of serum a-fetoprotein ranged from 0.1-376.200 ng/mL (mean. 2094 ng/mLl. The surgical procedure was comprised of 2 trisegmentectomies (0.7%). 8 bisegmentectomies (2.7%). 30 segmentectomies (10.2%) . 57 subsegmentectomies (19.4%) . and 197 nonanatomic limited resections (less extensive than subsegmentectomyl (67.0%). The details of the surgical techniques were reported previously.lo During the same period. no liver transplantation was performed at either NCCH or in Japan.
Orthotopic Liver Transplantation Group
Between 1981-1997. 307 patients underwent OLTx in the presence of HCC at the University of Pittsburgh Medical Center (Pittsburgh. PA). Portions of this experience were reported previously.III.2:! Of the 307 transplanted patients. 283 (92.1%) had concomitant cirrhosis. Thirteen of the 283 patients (4.6%) had microscopic positive margins due to extrahepatic extension of the rumor. The remaining 270 cirrhotic patients who underwent complete removal of the tumorts) bv OLTx were selected for the study. The follow-up period ranged from 3-201 months (median. 36.6 months). Eighty-seven patients (32.2%) had HCCs that were undetected preoperativelv. Cyclosporine and steroids were lIsed as immunosuppressive therapy between 1981-1989: tacrolimus replaced cyclosporine beginning at the end of 1989. Immunosuppressive therapy and the OL Tx technique were descnbed previously.':.!·:!' One hundred and one patients underwent hepatic resection for HCC between. 1980-1997 at Pittsburgh University Hospital.
Patient Characteristics
The patients' characteristics are shown in Table 1 . The mean age of the patients was lower in the OLTx group and the incidence of viral hepatitis as the etiology of the cirrhosis was higher in the Hx group. Although there was no significant difference in the mean tumor size (P = 0.08). tumors measuring ::::;2 cm and those measuring >5 cm in greatest dimension were more frequent in the OLTx group than in the Hx group. The OLTx patients had significantly more bilobar tumors compared with Hx patients. The overall incidence of vascular invasion was similar between the two groups; however. macroscopic vascular involvement was observed more frequently in the OLTx group (17.7%) than in the Hx group (7.2%). With regard to the histologic differentiation of HCC. the Hx group contained more patients with poorly differentiated tumors than the OLTx group. When stratified according to the pTNM staging system. 25 
Statistical Analysis
The Statistical Package for Social Science software (SPSS. Inc .• Chicago. IL) was used for data analysis. The Kaplan-Meier product-limit method with the log rank test was used to evaluate tumor free and patient survival rates for various prognostic factors. Results were reported as the mean :!: the standard error of the mean (SE). Significance levels were set at P < 0.05.
RESULTS
Surgical Mortality and Short Term Results
Four patients in the Hx group died within 1 month after surgery (surgical mortality rate: 1 h The avera~e ages were compared bva two'lalled Student I test tar paIred data .
• These pauentS Included those w1Ih VIral hepalllls before the test tor the hepallus C 11 rus was IVllIable.
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P<0.0001 There was no significant difference in overall survival
During the follow-up period. 176 of 294 patients in the Hx group (59.9%) and 53 of 270 patients in the OLTx group (19.6%) developed tumor recurrence. Cumulative I-year. 3-year. 5-year. and 7-year tumor free survival rates in the OLTx group were 75.2%. 63.1%. 53.9%. and 44.4%. respectively. and were 67.8%. 24.1%. 14.3%. and 7.2%. respectively. in the Hx group (Fig. 1 b) . The difference was statistically significant (P < O.OOOll .
Prognostic Factors
The influence of various prognostic factors on overall and tumor free survival is shown in Table 2 .
The tumor free survival rate of the OLTx group was significantly higher than that of the Hx group for tumors measuring s5 em, unilobarly distributed tumors, tumors with no or only microscopic vascular invasion. and tumors of well or moderate histologic differentiation (Table 2 ). However. when the tumors measured >5 cm or had macroscopic vascular invasion or poorly differentiated histology, there was no statistically significant difference in tumor free survival between the Hx and the OLTx groups. Lymph node status could not be analyzed because lymph node metastasis was so rare for both groups (one case in the Hx group and five cases in the OLTx group).
Specific Comparisons
The majority of liver transplantation centers no longer consider patients for OLTx if the HCC invades the major vascular branches or regional lymph nodes or if the patient has distant metastases. Overall and tumor free survival rates for the patients with tumors without macroscopic vascular invasion. regional lymph node metastases. or distant metastases were compared between 287 patients in the Hx group and 230 patients in the OLTx group (Figs. 2a and 2b ). In this subgroup of patients both the overall and tumor free survival rates in the OLTx group were significantly higher than those in the Hx group.
Uver transplantation primarily is the treatment of hepatic failure. Should HCC in those patients with well compensated cirrhosis be treated with transplantation? To answer this question. 193 patients in the Hx group with good hepatic function (Child-Pugh Grade A) without macroscopic vascular invasion. regional lymph node metastases. or distant metastases were selected. The overall and tumor free survival rates of 193 patients in the Hx group was compared with that of 230 patients in the OLTx group (all Child-Pugh grades) with the same tumor characteristics (Le .
• no macroscopic vascular invasion. regional lymph node metastases. or distant metastases). As shown in Fig- ures 3a and 3b, overall survival after Hx in this subgroup was similar to that after OLTx (P = 0.25), although the tumor free survival rate was significantly lower in the Hx group (P < 0.0001).
DISCUSSION
Subtotal hepatectomy or hepatic resection is used to treat HCC of limited number and size in patients with compensated cirrhosis. Total hepatectomy and liver replacement or OLTx primarily is the treatment of choice for hepatic failure although it can be used to treat HCCs of any number and size even in patients with decompensated cirrhosis. The prognosis of patients with advanced stage HCC (HCC with macroscopic vascular invasion. lymph node involvement, and distant metastases) is very poor after either hepatic resection or transplantation. 17.18.26.27 In this study. two large series of HCC patients with cirrhosis treated by different surgical strategies at institutions in Japan and the U. S. were compared ret- rospectively. There was a difference in the etiology and hepatic functional reserve between the two groups. Our study reconfirmed the findings of other reports that in patients with early stage HCC (HCC without macroscopic vascular invasion. lymph node involvement. or distant metastases). hepatic resection can provide excellent survival for those patients with good liver function,8.10.11 but the incidence of tumor recurrence after resection is extremely high when compared with that after transplantation. 14 -19 Should this then lead to the conclusion that all early stage HCC patients should be treated with transplantation regardless of hepatic function? As indicated in this study and others. 13 . 17 surgical and perioperative mortality is significantly higher after transplantation than after hepatic resection. The overall survival rate actually was higher for the initial 3-4 years after hepatic resection than transplantation (Fig. 3a) . despite the higher incidence of tumor recurrence after resection (Fig. 3b) .
In the Hx group the patients with recurrent HCC were treated effectively with reresection (20 patients). ethanol injection (18 patients). and chemoembolization (87 patients) ' or a combination thereof. Conversely. the recurrent tumors in the OLTx group were widespread and rarely could be treated by regional therapy. The mean survival after tumor recurrence was 31.6 :t 21.5 months (mean :t SE) in the Hx group and 15.3 :t 14.5 months (mean := SE) in the OLTx group (P < 0.001). Tumor growth under immunosuppression appeared to be accelerated. 21l
Within 5 years. 143 patients died after resection and 114 patients died after transplantation. One hundred of the 143 patients (69.9%) died with tumor recurrence after resection. and 41 of the 114 patients (36.0%) patients died after transplantation. After 5 years. 35 patients died after resection and 17 patients died after transplantation. Ten of the 35 patients (28.6%) in the Hx group and 13 of the 17 patients (76.5%) patients in the OLTx group died free of rumor. Thus. the incidence of death unrelated to HCC was significantly higher in transplantation group than in the resection group both within and after 5 years (P < 0.00001 and P = 0.001. respectively). The cirrhotic HCC patients who were treated by hepatic resection most often died with HCC ur of the complications of hepatic failure and portal hypertension. When those patients were treated by liver transplantation. the deaths related to HCC ur cirrhosis could be avoided either largely or entirely. However. the mortality inherent to transplantation. such as death due to infection and rejection. still affected the survival rates.
Liver transplantation should be avoided in HCC pauents with macroscopic vascular invasion. J\'mph node involvement. or distant metastases. 18 . 19 Hepatic resection for HCC in patients with concomitant cirrhosis should be limited to patients with good hepatic function. Tumor recurrence should be monitored very closely after resection. and recurrent tumors should be treated aggressively with reresection, chemical or thermal ablation. and/or arterial chemoembolization. With this approach the survival of patients with good hepatic function should be as good as that of patients who undergo liver transplantation. as indicated in this study. When liver function begins to deteriorate and! or when the recurrent tumors appear to be better treated by liver replacement. liver transplantation may be considered. Longitudinal therapeutic planning (hepatic resection followed by aggressive regional therapy as described earlier and liver transplantation) may improve survival further for the patients with HCC with compensated cirrhosis. We believe patients with fair or poor liver function are best treated with liver transplantation. providing the HCC does not invade major branches of hepatic vessels and does not have lymph node or distant metastases. In the face of organ shortage, the use of liver transplantation for HCC should be limited to good risk patients as indicated in this study and others.lHo
